ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Emetic risk of single intravenous antineoplastic agents in adults

Emetic risk of single intravenous antineoplastic agents in adults
Risk level Agent
High (>90%) Anthracycline/cyclophosphamide combination
Carmustine
Cisplatin
Cyclophosphamide ≥1500 mg/m2
Dacarbazine
Mechlorethamine
Streptozocin
Moderate (30 to 90%) Alemtuzumab
Arsenic trioxide
Azacitidine
Bendamustine
Busulfan*
Carboplatin
Clofarabine
Cyclophosphamide <1500 mg/m2
Cytarabine >1000 mg/m2
Daunorubicin
Daunorubicin and cytarabine liposome
Doxorubicin
Epirubicin
Fam-trastuzumab deruxtecan-nxki
Idarubicin
Ifosfamide
Irinotecan
Irinotecan liposomal injection
Oxaliplatin
Romidepsin
Temozolomide
ThiotepaΔ
Trabectedin
Low (10 to 30%) Aflibercept
Axicabtagene ciloleucel
Belinostat
Blinatumomab
Bortezomib
Brentuximab
Cabazitaxel
Carfilzomib
Catumaxumab
Cetuximab
Copanlisib
Cytarabine ≤1000 mg/m2
Decitabine
Docetaxel
Elotuzumab
Enfortumab vedotin-ejfv
Eribulin
Etoposide
Fluorouracil
Risk level Agent
Low (10 to 30%)
(continued)		 Gemcitabine
Gemtuzumab ozogamicin
Inotuzumab ozogamicin
Ixabepilone
Methotrexate
Mitomycin
Mitoxantrone
Moxetumomab pasudotox
Nab-paclitaxel
Necitumumab
Nelarabine
Paclitaxel
Panitumumab
Pegylated liposomal doxorubicin
Pemetrexed
Pertuzumab
Tagraxofusp-erzs
Temsirolimus
Tisagenlecleucel
Topotecan
Trastuzumab-emtansine
Vinflunine
Minimal (<10%) Atezolizumab
Avelumab
Bevacizumab
Bleomycin
 
Cemiplimab
2-Chlorodeoxyadenosine
Cladribine
Daratumumab
Durvalumab
Emapalumab
Fludarabine
Ipilimumab
Nivolumab
Obinutuzumab
Ofatumumab
Pembrolizumab
Pixantrone
Polatuzumab vedotin
Pralatrexate
Ramucirumab
Rituximab
Trastuzumab
Vinblastine
Vincristine
Vinorelbine
* Reclassified based on errata.[1]
¶ No direct evidence found for intravenous temozolomide; because all sources indicate a similar safety profile to the oral formulation, the classification was based on oral temozolomide.
Δ Classification refers to individual evidence from pediatric trials.
Reference:
  1. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update: Errata. J Clin Oncol 2020; 38:3825
Reproduced with permission from: Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol 2020; 38:JCO2001296. Copyright © 2020 American Society of Clinical Oncology. All rights reserved.
Graphic 58756 Version 41.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟